Skip to main content
SpringerLink
Log in

Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Epigenetics refers to the study of clonally inherited changes in gene expression without accompanying genetic changes. Previous research on the epigenetics of myelodysplastic syndromes (MDS) mainly focused on the inactivation of tumor suppressor genes as a result of DNA methylation. However, the basic molecular pathogenesis of epigenetics in MDS remains poorly understood. Recent studies have revealed that DNA methylation and histone modification may be controlled by Polycomb-group (PcG) proteins, which may give new clues toward understanding the epigenetic mechanism of MDS. In this study, we explored for the first time the expression of PcG genes, including EZH2, EED, SUZ12, RING1, and BMI1, in various MDS subsets and acute myeloid leukemia (AML), as well as the relationship between the expression of PcG genes and epigenetic alteration and prognosis-risk scoring. Patients with MDS/AML showed overexpression of EZH2, RING1, and BMI1 genes compared to their expression levels in patients with non-clonal cytopenia diseases. The MDS patients with DNA methylation had higher EZH2 expression than those without DNA methylation. The patients who received decitabine treatment presented significantly reduced expression of EZH2 and RING1 besides decreased p15INK4B methylation after decitabine treatment. Moreover, overexpression of EZH2, RING1, and BMI1 was always linked to poor prognostic scoring. In conclusion, overexpression of the EZH2, RING1, and BMI1 genes is common in MDS and indicate poor prognosis. The products of these genes might participate in epigenetic regulation of MDS. These studies may also contribute to our understanding of the effective mechanism of decitabine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7:118–129

    Article  PubMed  CAS  Google Scholar 

  2. Tiu R, Gondek L, O'Keefe C, Maciejewski JP (2007) Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 21:1648–1657

    Article  PubMed  CAS  Google Scholar 

  3. Fenaux P, Mufti GL, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  PubMed  CAS  Google Scholar 

  4. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850–1856

    Article  PubMed  CAS  Google Scholar 

  5. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803

    Article  PubMed  CAS  Google Scholar 

  6. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52–57

    Article  PubMed  CAS  Google Scholar 

  7. Grønbaek K, Hother C, Jones PA (2007) Epigenetic changes in cancer. APMIS 115:1039–1059

    Article  PubMed  Google Scholar 

  8. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597–610

    Article  PubMed  CAS  Google Scholar 

  9. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J, Herman JG (2002) Cancer epigenetics and methylation. Science 297:1807–1808

    Article  PubMed  Google Scholar 

  10. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428

    Article  PubMed  CAS  Google Scholar 

  11. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I, Cedar H (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39:232–236

    Article  PubMed  CAS  Google Scholar 

  12. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, Issa JP (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741–750

    Article  PubMed  CAS  Google Scholar 

  13. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871–874

    Article  PubMed  Google Scholar 

  14. Rajasekhar VK, Begemann M (2007) Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25:2498–2510

    Article  PubMed  CAS  Google Scholar 

  15. Levine SS, King IF, Kingston RE (2004) Division of labor in polycomb group repression. Trends Biochem Sci 29:478–485

    Article  PubMed  CAS  Google Scholar 

  16. Bantignies F, Cavalli G (2006) Cellular memory and dynamic regulation of polycomb group proteins. Curr Opin Cell Biol 18:275–283

    Article  PubMed  CAS  Google Scholar 

  17. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ (2004) Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 18:1592–1605

    Article  PubMed  CAS  Google Scholar 

  18. Cao R, Zhang Y (2004) SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 15:57–67

    Article  PubMed  CAS  Google Scholar 

  19. Cao R, Tsukada Y, Zhang Y (2005) Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 20:845–854

    Article  PubMed  CAS  Google Scholar 

  20. Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ (2008) Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood 111:2621–2630

    Article  PubMed  CAS  Google Scholar 

  21. Aoki E, Ohashi H, Uchida T, Murate T, Saito H, Kinoshita T (2003) Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes. Leukemia 17:1903–1904

    Article  PubMed  CAS  Google Scholar 

  22. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P (2006) Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76:23–32

    Article  PubMed  CAS  Google Scholar 

  23. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, Hohaus S, Leone G (2004) Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103:698–700

    Article  PubMed  CAS  Google Scholar 

  24. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, Huang SY, Tsay W, Chen YC, Shen MC, Wang CH, Yeh YC, Tien HF (2006) Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 135:317–323

    Article  PubMed  CAS  Google Scholar 

  25. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736

    Article  PubMed  Google Scholar 

  26. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302

    Article  PubMed  CAS  Google Scholar 

  27. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088

    PubMed  CAS  Google Scholar 

  28. Bennett JM, Catovsky D, Daniel MT (1976) Proposals for the classification of the acute leukaemias: French-American-British co-operative group. Br J Haematol 33:451–458

    Article  PubMed  CAS  Google Scholar 

  29. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425

    Article  PubMed  CAS  Google Scholar 

  30. Gil J, Bernard D, Peters G (2005) Role of polycomb group proteins in stem cell self-renewal and cancer. DNA cell boil 24:117–125

    Article  CAS  Google Scholar 

  31. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605–613

    Article  PubMed  CAS  Google Scholar 

  32. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448–3458

    Article  PubMed  CAS  Google Scholar 

  33. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–1325

    Article  PubMed  CAS  Google Scholar 

  34. Sánchez-Beato M, Sánchez E, González-Carreró J, Morente M, Díez A, Sánchez-Verde L, Martín MC, Cigudosa JC, Vidal M, Piris MA (2006) Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 19:684–694

    Article  PubMed  Google Scholar 

  35. Beà S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D, Campo E (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409–2412

    PubMed  Google Scholar 

  36. Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45:639–645

    Article  PubMed  Google Scholar 

  37. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29

    PubMed  CAS  Google Scholar 

  38. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti GJ (2007) CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937–1944

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

None

Fund

This project was funded by Appropriate Technology Program, Shanghai Shen Kang Hospital Development Centre, China (Item No. SHDC12010202)

Author information

Authors and Affiliations

  1. Department of Hematology, The Sixth people Hospital, Shanghai JiaoTong University, ShangHai Jiaotong University School of Medicine, Building NO 600, Yishan Road, Shanghai, 200233, People’s Republic of China

    Feng Xu, Xiao Li, Lingyun Wu, Qingxia Zhang, Rui Yang, Yujuan Yang, Zheng Zhang, Qi He & Chunkang Chang

Authors
  1. Feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lingyun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qingxia Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yujuan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qi He
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chunkang Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, F., Li, X., Wu, L. et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 90, 643–653 (2011). https://doi.org/10.1007/s00277-010-1128-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1128-5

Keywords

Search

Navigation